-
1
-
-
62549157097
-
HCV-related burden of disease in Europe: A systematic assessment of incidence, prevalence, morbidity, and mortality
-
Muhlberger, N; Schwarzer, R; Lettmeier, B; et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009; 9: 34.
-
(2009)
BMC Public Health
, vol.9
, pp. 34
-
-
Muhlberger, N.1
Schwarzer, R.2
Lettmeier, B.3
-
2
-
-
77953123259
-
Mortality in patients with chronic and cleared hepatitis C viral infection: A nationwide cohort study
-
Omland, LH; Krarup, H; Jepsen, P; et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010; 53: 36-42.
-
(2010)
J Hepatol
, vol.53
, pp. 36-42
-
-
Omland, L.H.1
Krarup, H.2
Jepsen, P.3
-
3
-
-
36549067746
-
The changing epidemiology of hepatitis C virus infection in Europe
-
DOI 10.1016/j.jhep.2007.07.033, PII S0168827807005739
-
Esteban, JI; Sauleda, S; Quer, J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148-162. (Pubitemid 350191999)
-
(2008)
Journal of Hepatology
, vol.48
, Issue.1
, pp. 148-162
-
-
Esteban, J.I.1
Sauleda, S.2
Quer, J.3
-
4
-
-
79960453276
-
EASL clinical practice guidelines: Management of chronic hepatitis C virus infection
-
European association for the study of the liver
-
European association for the study of the liver. EASL clinical practice guidelines: management of chronic hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
-
(2011)
J Hepatol
, vol.55
, pp. 245-264
-
-
-
5
-
-
0037063113
-
Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection
-
DOI 10.1056/NEJMoa013376
-
Hermine, O; Lefrère, F; Bronowicki, JP; et al. Regression of splenic lymphoma with lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94. (Pubitemid 34753478)
-
(2002)
New England Journal of Medicine
, vol.347
, Issue.2
, pp. 89-94
-
-
Hermine, O.1
Lefrere, F.2
Bronowicki, J.-P.3
Mariette, X.4
Jondeau, K.5
Eclache-Saudreau, V.6
Delmas, B.7
Valensi, F.8
Cacoub, P.9
Brechot, C.10
Varet, B.11
Troussard, X.12
-
6
-
-
0034221590
-
Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa
-
Fontaine, H; Chaix, ML; Lagneau, JL; et al. Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa. Lancet 2000; 356: 41. (Pubitemid 30416995)
-
(2000)
Lancet
, vol.355
, Issue.9223
, pp. 41
-
-
Fontaine, H.1
Chaix, M.-L.2
Lagneau, J.-L.3
Brechot, C.4
Pol, S.5
-
7
-
-
68249154875
-
Peginterferon alfa-2b or alfa-2a with ribavirin for treatement of hepatitis C infection
-
Mchutchison, JG; Lawitz, EJ; Shiffman, ML; et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatement of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
-
(2009)
N Engl J Med
, vol.361
, pp. 580-593
-
-
McHutchison, J.G.1
Lawitz, E.J.2
Shiffman, M.L.3
-
8
-
-
38449091418
-
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
-
Veldt, BJ; Heathcote, EJ; Wedemeyer, H; et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-684. (Pubitemid 351664462)
-
(2007)
Annals of Internal Medicine
, vol.147
, Issue.10
, pp. 677-684
-
-
Veldt, B.J.1
Heathcote, E.J.2
Wedemeyer, H.3
Reichen, J.4
Hofmann, W.P.5
Zeuzem, S.6
Manns, M.P.7
Hansen, B.E.8
Schalm, S.W.9
Janssen, H.L.A.10
-
9
-
-
51949117672
-
Brief communication: The relationship of regression of cirrhosis to outcome in chronic hepatitis C
-
Mallet, V; Gilgenkrantz, H; Serpaggi, J; et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403.
-
(2008)
Ann Intern Med
, vol.149
, pp. 399-403
-
-
Mallet, V.1
Gilgenkrantz, H.2
Serpaggi, J.3
-
10
-
-
84866898184
-
Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community-based long-term prospective study
-
Lee, MH; Yang, HI; Lu, SN; et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206: 469-477.
-
(2012)
J Infect Dis
, vol.206
, pp. 469-477
-
-
Lee, M.H.1
Yang, H.I.2
Lu, S.N.3
-
11
-
-
84864915019
-
Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus
-
Berenguer, J; Rodríguez, E; Miralles, P; et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012; 55: 728-736.
-
(2012)
Clin Infect Dis
, vol.55
, pp. 728-736
-
-
Berenguer, J.1
Rodríguez, E.2
Miralles, P.3
-
12
-
-
34249024924
-
Replication of hepatitis C virus
-
DOI 10.1038/nrmicro1645, PII NRMICRO1645
-
Moradpour, D; Penin, F; Rice, CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463. (Pubitemid 46780082)
-
(2007)
Nature Reviews Microbiology
, vol.5
, Issue.6
, pp. 453-463
-
-
Moradpour, D.1
Penin, F.2
Rice, C.M.3
-
13
-
-
84855212109
-
New targets for antiviral therapy of chronic hepatitis C
-
Buhler, S; Bartenschlager, R. New targets for antiviral therapy of chronic hepatitis C. Liver Int 2012; 32: 19-16.
-
(2012)
Liver Int
, vol.32
, pp. 19-16
-
-
Buhler, S.1
Bartenschlager, R.2
-
14
-
-
82955236108
-
Anti-HCV drugs in the pipeline
-
Yang, PL; Gao, M; Lin, K; et al. Anti-HCV drugs in the pipeline. Curr Opin Virol 2011; 1: 607-616.
-
(2011)
Curr Opin Virol
, vol.1
, pp. 607-616
-
-
Yang, P.L.1
Gao, M.2
Lin, K.3
-
15
-
-
65449171953
-
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
-
Hezode, C; Forestier, N; Dusheiko, G; et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
-
(2009)
N Engl J Med
, vol.360
, pp. 1839-1850
-
-
Hezode, C.1
Forestier, N.2
Dusheiko, G.3
-
16
-
-
77956268467
-
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentric phase 2 trial
-
Kwo, PY; Lawitz, EJ; McCone, J; et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentric phase 2 trial. Lancet 2011; 376: 705-716.
-
(2011)
Lancet
, vol.376
, pp. 705-716
-
-
Kwo, P.Y.1
Lawitz, E.J.2
McCone, J.3
-
17
-
-
77950817619
-
Telaprevir for previously treated chronic HCV infection
-
McHutchison, JG; Manns, MP; Muir, AJ; et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
-
(2010)
N Engl J Med
, vol.362
, pp. 1292-1303
-
-
McHutchison, J.G.1
Manns, M.P.2
Muir, A.J.3
-
18
-
-
79959381354
-
Telaprevir for retreatment of HCV infection
-
Zeuzem, S; Andreone, P; Pol, S; et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
-
(2011)
N Engl J Med
, vol.364
, pp. 2417-2428
-
-
Zeuzem, S.1
Andreone, P.2
Pol, S.3
-
19
-
-
79953176289
-
Boceprevir for previously treated chronic HCV genotype 1 infection
-
Bacon, BR; Gordon, SC; Lawitz, E; et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
-
(2011)
N Engl J Med
, vol.364
, pp. 1207-1217
-
-
Bacon, B.R.1
Gordon, S.C.2
Lawitz, E.3
-
20
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
Jacobson, IM; McHutchison, JG; Dusheiko, G; et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
-
21
-
-
84855924980
-
Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals
-
Cacoub, P; Bourlière, M; Lübbe, J; et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012; 56: 455-463.
-
(2012)
J Hepatol
, vol.56
, pp. 455-463
-
-
Cacoub, P.1
Bourlière, M.2
Lübbe, J.3
-
23
-
-
84878976866
-
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype 1, infection (ATOMIC): An open-label, randomised, multicentre, phase 2 trial
-
Kowdley, KV; Lawitz, E; Crespo, I; et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype 1, infection (ATOMIC): an open-label, randomised, multicentre, phase 2 trial. Lancet 2013; 381: 2100-2107.
-
(2013)
Lancet
, vol.381
, pp. 2100-2107
-
-
Kowdley, K.V.1
Lawitz, E.2
Crespo, I.3
-
24
-
-
78049527728
-
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and Danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): A randomised, double-blind, placebo-controlled, dose-escalation trial
-
Gane, EJ; Roberts, SK; Stedman, CA; et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and Danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-1475.
-
(2010)
Lancet
, vol.376
, pp. 1467-1475
-
-
Gane, E.J.1
Roberts, S.K.2
Stedman, C.A.3
-
25
-
-
84865285928
-
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: A randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
-
Pol, S; Ghalib, RH; Rustgi, VK; et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012; 12: 671-677.
-
(2012)
Lancet Infect Dis
, vol.12
, pp. 671-677
-
-
Pol, S.1
Ghalib, R.H.2
Rustgi, V.K.3
-
26
-
-
81855228070
-
Efficacy of the protease inhibitor BI 201335, the polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C
-
Zeuzem, S; Asselah, T; Angus, PW; et al. Efficacy of the protease inhibitor BI 201335, the polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C. Gastroenterology 2011; 141: 2047-2055.
-
(2011)
Gastroenterology
, vol.141
, pp. 2047-2055
-
-
Zeuzem, S.1
Asselah, T.2
Angus, P.W.3
-
27
-
-
84874105854
-
Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202)
-
Lenz, O; Vijgen, L; Berke, JM; et al. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 2013; 58: 445-451.
-
(2013)
J Hepatol
, vol.58
, pp. 445-451
-
-
Lenz, O.1
Vijgen, L.2
Berke, J.M.3
-
28
-
-
84856159009
-
Preliminary study of two antiviral agents for hepatitis C genotype 1
-
Lok, AS; Gardiner, DF; Lawitz, E; et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224.
-
(2012)
N Engl J Med
, vol.366
, pp. 216-224
-
-
Lok, A.S.1
Gardiner, D.F.2
Lawitz, E.3
-
29
-
-
84871814966
-
Nucleotide polymerase inhibitor Sofosbuvir plus ribavirin for hepatitis C
-
Gane, EJ; Stedman, CA; Hyland, RH; et al. Nucleotide polymerase inhibitor Sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.
-
(2013)
N Engl J Med
, vol.368
, pp. 34-44
-
-
Gane, E.J.1
Stedman, C.A.2
Hyland, R.H.3
-
30
-
-
84889666210
-
Exploratory study of oral combination antiviral therapy for hepatitis C
-
Poordard, F; Lawitz, E; Kowdley, KV; et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 56: S560.
-
(2013)
N Engl J Med
, vol.56
-
-
Poordard, F.1
Lawitz, E.2
Kowdley, K.V.3
|